We have a diverse pipeline designed to make a meaningful difference for patients
Our growing development pipeline of innovative new therapies is driven by the flexibility of our TransCon™ technologies. We have multiple prodrug therapies in development. Each candidate is unique and designed to be a best-in-class therapy.
We have three product candidates in endocrinology rare diseases. And we are advancing multiple candidates in oncology, our second therapeutic area. This pipeline showcases how we apply our scientific approach to address unmet medical needs and aim to improve patients’ lives.
Endocrinology Rare Diseases1
(Outside the U.S.)
MAA Submitted in Europe 20203
MAA Submitted in Europe 20203
Oncology4
1 Rights in Greater China granted to VISEN Pharmaceuticals.
2 In phase 3 development in Greater China through strategic investment in VISEN Pharmaceuticals. Ascendis Pharma is conducting a phase 3 trial in Japan.
3 Medical Authorisation Application (MAA) submitted to the European Medicines Agency in September 2020. Approved by US FDA August 25, 2021.
4 Ascendis Pharma holds all global commercial rights.
Explore
